Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review

References

• Lorenzoni V, Baccetti F, Genovese S, et al. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. Clinicoecon Outcomes Res. 2017;9:699–710.
   PubMed Web of Science ®Google Scholar
• Federation ID. IDF diabetes atlas, 9th edn; 2019 [cited 2020 Aug 7]. Available from: https://www.diabetesatlas.org/en
   Google Scholar
• Organization WH. Global status report on noncommunicable diseases; 2010. Available from: http://www.who.int/nmh/publications/ncd_report2010/en
   Google Scholar
• Jaacks LM, Siegel KR, Gujral UP, et al. Type 2 diabetes: a 21st century epidemic. Best Pract Res Cl En. 2016 Jun;30 331–343.
   PubMed Web of Science ®Google Scholar
• Bae JH, Kim S, Park EG, et al. Effects of Dipeptidyl Peptidase-4 Inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Endocrinol Metab. 2019 Mar;34:80–92.
   Google Scholar
• Gordon J, McEwan P, Hurst M, et al. The cost-effectiveness of alogliptin versus Sulfonylurea as add-on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Therapy. 2016 Dec;7:825–845.
   PubMed Web of Science ®Google Scholar
• Viriato D, Calado F, Gruenberger J-B, et al. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. J Med Econ. 2014 Jul;17(7):499–507.
   PubMedGoogle Scholar
• Gu SY, Deng J, Shi LZ, et al. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in type 2 diabetes in China. J Med Econ. 2015;18(10):808–820.
   PubMed Web of Science ®Google Scholar
• Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obesity Metab. 2008 Jun;10(s1):43–55.
   PubMedGoogle Scholar
• Geng JS, Yu H, Mao YW, et al. Cost effectiveness of Dipeptidyl Peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics. 2015 Jun;33:581–597.
   PubMed Web of Science ®Google Scholar
• Hong DZ, Si L, Jiang MH, et al. Cost effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and Dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review (vol 37, pg 777, 2019). Pharmacoeconomics. 2019 Dec;37:1553.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013 Mar-Apr;16:231–250.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Arnoldini S, Hunt B, et al. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: a long-term cost-effectiveness analysis. Diabetes Obes Metab. 2018 Aug;20:1921–1927.
   PubMed Web of Science ®Google Scholar
• Elgart JF, Caporale JE, Gonzalez L, et al. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Econ Rev. 2013 Apr 27;3:11.
   PubMedGoogle Scholar
• Bain SC, Hansen BB, Malkin SJP, et al. Oral Semaglutide versus Empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Ther. 2020 Jan;11:259–277.
   PubMed Web of Science ®Google Scholar
• Bruhn D, Martin AA, Tavares R, et al. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. J Med Econ. 2016 Jul;19:672–683.
   PubMed Web of Science ®Google Scholar
• Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective. BMC Health Serv Res. 2015;15:496.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Chubb BD, Smith IC, et al. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in type 2 diabetes mellitus. Diabet Med. 2012 Mar;29:313–320.
   PubMed Web of Science ®Google Scholar
• Grzeszczak W, Czupryniak L, Kolasa K, et al. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol Ther. 2012 Jan;14:65–73.
   PubMed Web of Science ®Google Scholar
• Gu S, Zeng Y, Yu D, et al. Cost-effectiveness of saxagliptin versus acarbose as second-line therapy in type 2 diabetes in China. PLoS One. 2016;11:e0167190.
   PubMed Web of Science ®Google Scholar
• Guillermin AL, Lloyd A, Best JH, et al. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ. 2012;15:654–663.
   PubMedGoogle Scholar
• Kiadaliri AA, Gerdtham UG, Eliasson B, et al. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in Sweden. Diabetes Ther. 2014 Dec;5:591–607.
   PubMed Web of Science ®Google Scholar
• Klarenbach S, Cameron C, Singh S, et al. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ. 2011 Nov 8;183:E1213–20.
   PubMed Web of Science ®Google Scholar
• Kousoulakou H, Hatzikou M, Baroutsou V, et al. Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece. Cost Eff Resour Alloc. 2017;15:19.
   PubMed Web of Science ®Google Scholar
• Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. BMC Health Serv Res. 2018 Feb 1;18:78.
   PubMed Web of Science ®Google Scholar
• Lee WC, Samyshkin Y, Langer J, et al. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE diabetes model analysis. J Med Econ. 2012;15(Suppl 2):28–37.
   PubMedGoogle Scholar
• Mezquita Raya P, Pérez A, Ramírez de Arellano A, et al. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther. 2013 Dec;4:417–430.
   PubMed Web of Science ®Google Scholar
• Pérez A, Mezquita Raya P, Ramírez de Arellano A, et al. Cost-effectiveness analysis of incretin therapy for type 2 diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. Diabetes Ther. 2015 Mar;6:61–74.
   PubMed Web of Science ®Google Scholar
• Permsuwan U, Dilokthornsakul P, Saokaew S, et al. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand. Clinicoecon Outcomes Res. 2016;8:521–529.
   PubMedGoogle Scholar
• Permsuwan U, Dilokthornsakul P, Thavorn K, et al. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. J Med Econ. 2017;20:171–181.
   PubMed Web of Science ®Google Scholar
• Ramos M, Foos V, Ustyugova A, et al. Cost-effectiveness analysis of Empagliflozin in comparison to sitagliptin and saxagliptin based on cardiovascular outcome trials in patients with type 2 diabetes and established cardiovascular disease. Diabetes Ther. 2019 Dec;10:2153–2167.
   PubMed Web of Science ®Google Scholar
• Reifsnider O, Kansal A, Pimple P, et al. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. Diabetes Obes Metab. 2021 Mar;23:791–799.
   PubMed Web of Science ®Google Scholar
• Watada H, Sakamaki H, Yabe D, et al. Cost-effectiveness analysis of linagliptin in Japan based on results from the Asian subpopulation in the CARMELINA((R)) trial. Diabetes Ther. 2020 Aug;11:1721–1734.
   PubMed Web of Science ®Google Scholar
• Torre E, Bruno GM, Di Matteo S, et al. Cost-utility analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and insulin glargine: economic implications of the outcomes of the CVD-real studies I and II. Health Serv Insights. 2020;13:1178632920929982.
   Web of Science ®Google Scholar
• Van der Linden N, Van Olst S, Nekeman S, et al. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands. Diabet Med. 2020;3:e14371.
   Google Scholar
• Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm. 2013 Apr;19:237–246.
   PubMed Web of Science ®Google Scholar
• Hu S, Deng X, Ma Y, et al. Cost-Utility analysis of dapagliflozin versus saxagliptin treatment as monotherapy or combination therapy as add-on to metformin for treating type 2 diabetes mellitus. Appl Health Econ Health Policy. 2021 Jan;19:69–79.
   PubMed Web of Science ®Google Scholar
• Martin V, Vidal J, Malkin SJP, et al. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide and sitagliptin in the Spanish setting. Adv Ther. 2020 Oct;37:4427–4445.
   PubMed Web of Science ®Google Scholar
• Neslusan C, Teschemaker A, Johansen P, et al. Cost-effectiveness of canagliflozin versus sitagliptin as add-on to metformin in patients with type 2 diabetes mellitus in Mexico. Value Health Reg Issues. 2015 Dec;8:8–19.
   PubMedGoogle Scholar
• Tzanetakos C, Tentolouris N, Kourlaba G, et al. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Investig. 2016 Aug;36:649–659.
   PubMed Web of Science ®Google Scholar
• Tandon T, Dubey AK, Srivastava S, et al. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. J Family Med Prim Care. 2019 Mar;8:955–959.
   PubMedGoogle Scholar
• Sabapathy S, Neslusan C, Yoong K, et al. Cost-effectiveness of canagliflozin versus sitagliptin when added to metformin and sulfonylurea in type 2 diabetes in Canada. J Popul Ther Clin Pharmacol. 2016;23:e151–68.
   PubMed Web of Science ®Google Scholar
• Pawaskar M, Bilir SP, Kowal S, et al. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes. Am J Manag Care. 2019;25:231–238.
   PubMed Web of Science ®Google Scholar
• Granstrom O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012 Jul;6:127–136.
   PubMed Web of Science ®Google Scholar
• Erhardt W, Bergenheim K, Duprat-Lomon I, et al. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig. 2012 Mar 1;32:189–202.
   PubMed Web of Science ®Google Scholar
• De Oliveira GL, Guerra Júnior AA, Godman B, et al. Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17:109–119.
   PubMed Web of Science ®Google Scholar
• Brown ST, Grima DG, Sauriol L. Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus. Clin Ther. 2014 Nov 1;36:1576–1587.
   PubMed Web of Science ®Google Scholar
• Cazarim MD, da Cruz-cazarim ELC, Baldoni AD, et al. Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. Diabetes Metab Synd. 2017 Dec;11 S859–S65.
   PubMed Web of Science ®Google Scholar
• Teramachi H, Ohta H, Tachi T, et al. Pharmacoeconomic analysis of DPP-4 inhibitors. Pharmazie. 2013;68:909–915.
   PubMed Web of Science ®Google Scholar
• Ektare VU, Lopez JM, Martin SC, et al. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus. Am J Manag Care. 2014;20:S204–15.
   PubMed Web of Science ®Google Scholar
• Vidal J, Malkin SJP, Hunt B, et al. The short-term cost-effectiveness of once-weekly semaglutide versus once-daily sitagliptin and once-weekly dulaglutide for the treatment of patients with type 2 diabetes: a cost of control analysis in Spain. Diabetes Ther. 2020 Feb;11:509–521.
   PubMed Web of Science ®Google Scholar
• Ferrario MG, Lizán L, Montagnoli R, et al. Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: short-term cost-per-controlled patient in Italy. Prim Care Diabetes. 2016 Jun;10:220–226.
   PubMed Web of Science ®Google Scholar
• Deerochanawong C, Kosachunhanun N, Gadekar AV, et al. Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand. Clinicoecon Outcomes Res. 2019;11:423–430.
   PubMed Web of Science ®Google Scholar
• Chakravarty A, Rastogi M, Dhankhar P, et al. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. J Med Econ. 2018 May;21:497–509.
   PubMed Web of Science ®Google Scholar
• Steen Carlsson K, Persson U. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. J Med Econ. 2014 Sep;17:658–669.
   PubMedGoogle Scholar
• Skovgaard R, Jon Ploug U, Hunt B, et al. Evaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in Canada. Clin Ther. 2015 Aug;37:1677–1688.
   PubMed Web of Science ®Google Scholar
• Roussel R, Martinez L, Vandebrouck T, et al. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. J Med Econ. 2016;19:121–134.
   PubMed Web of Science ®Google Scholar
• Oksuz E, Malhan S, Urganci B, et al. Cost-minimization analysis of linagliptin compared to sitagliptin in the treatment of type 2 diabetes mellitus from a Turkish healthcare perspective. J Diabetes Metabol. 2017;08:739.
   Google Scholar
• Hunt B, Hansen BB, Ericsson A, et al. Evaluation of the cost per patient achieving treatment targets with oral semaglutide: a short-term cost-effectiveness analysis in the United States. Adv Ther. 2019 Dec;36:3483–3493.
   PubMed Web of Science ®Google Scholar
• Tamilselvan T, Kumutha T, Lekshmi VA, et al. Pharmacoeconomical evaluation of oral hypoglycemic agents for Type-2 diabetes mellitus in a multispeciality hospital. Int J Pharm Sci Res. 2017;8:2243–2248.
   Web of Science ®Google Scholar
• Nita ME, Eliaschewitz FG, Ribeiro E, et al. Cost-effectiveness and budget impact of saxagliptin as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system. Rev Assoc Med Bras. 2012;58:294–301.
   PubMed Web of Science ®Google Scholar
• Hunt B, Malkin SJP, Moes RGJ, et al. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Res Care. 2019;7:e000705.
   PubMed Web of Science ®Google Scholar
• Wang B, Sun Y, Sang Y, et al. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: a system review and meta-analysis. Medicine (Baltimore). 2018 Nov;97:e12633.
   PubMed Web of Science ®Google Scholar
• Min SH, Yoon JH, Moon SJ, et al. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep. 2018 Mar 13;8:4466.
   PubMed Web of Science ®Google Scholar
• Min SH, Yoon JH, Hahn S, et al. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: a systematic review with meta-analysis. J Diabetes Investig. 2018 Jul;9:893–902.
   PubMed Web of Science ®Google Scholar
• Yassin SA, Aroda VR. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Des Devel Ther. 2017;11:923–937.
   PubMed Web of Science ®Google Scholar
• Yamada T, Shojima N, Noma H, et al. Weekly versus daily dipeptidyl peptidase 4 inhibitor therapy for type 2 diabetes: systematic review and meta-analysis. Diabetes Care. 2018 Apr;41:e52–e55.
   PubMed Web of Science ®Google Scholar
• Stoimenis D, Karagiannis T, Katsoula A, et al. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opin Pharmacother. 2017 Jun;18:843–851.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Cheng X, Shao H, et al. A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes. Curr Diab Rep. 2020 Mar 12;20:12.
   PubMed Web of Science ®Google Scholar
• Zueger PM, Schultz NM, Lee TA. Cost effectiveness of liraglutide in type II diabetes: a systematic review. Pharmacoeconomics. 2014 Nov;32(11):1079–1091.
   PubMed Web of Science ®Google Scholar
• Ruan Z, Yang L, Shi H, et al. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):221–233.
   PubMed Web of Science ®Google Scholar
• Luo Z, Ruan Z, Yao D, et al. Budget impact analysis of diabetes drugs: a systematic literature review. Front Public Health. 2021;9:765999.
   PubMed Web of Science ®Google Scholar